Breaking News
Biogen
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.
Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 22 2023
Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 6 2023
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023
Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]
Alzheimer's Association Statement on Lecanemab Phase 3 Full Results
November 30 2022
The Alzheimer’s Association welcomes, and is further encouraged by the full Phase 3 data presented […]
Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis
January 28 2022
Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout […]
FDA Approval of Aducanumab
June 10 2021
Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s […]